N@N

Market Maker Surveillance Report. EMIS, LPHI, DBLE, TRGL, CPE, CRME, Losing Stocks With Lowest Price Friction For Monday, Febr

^{Published on 2011-02-07 17:51:36 - WOPRAI}
 

February 7, 2011 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 2568 companies with "abnormal" market making, 3415 companies with positive Friction Factors and 1968 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Monday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. EMISPHERE TECHNOLOGIES INC (OTCBB:EMIS), LIFE PARTNERS HOLDINGS INC (NASDAQ:LPHI), DOUBLE EAGLE PETROLEUM CO (NASDAQ:DBLE), TOREADOR RESOURCES CORP (NASDAQ:TRGL), CALLON PETROLEUM CO (NYSE:CPE), CARDIOME PHARMA CORPORATION (NASDAQ:CRME). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

     Symbol     Change       Percent      Buy Volume      Buy %%       Sell Volume     Sell %%      Net Volume      Friction
     EMIS       $-0.180      -10.91%      95,835          35.71%       172,504         64.29%       -76,669         -4,259  
     LPHI       $-0.800      -8.45%       243,779         41.77%       334,018         57.24%       -90,239         -1,128  
     DBLE       $-0.890      -8.44%       720,011         48.03%       762,368         50.86%       -42,357         -476    
     TRGL       $-1.780      -11.85%      875,637         47.80%       946,206         51.65%       -70,569         -396    
     CPE        $-1.190      -12.95%      927,570         43.47%       1,110,957       52.06%       -183,387        -1,541  
     CRME       $-0.690      -10.10%      475,851         49.83%       478,235         50.08%       -2,384          -35     

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net dollar losses (Change) and extremely low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows CRME with a dollar loss Monday of $-0.69000 and a Friction Factor of -35 shares. That means that it only took 35 more shares of selling than buying to move CRME lower by one penny. This means the Market Makers are allowing the stock to drop quickly (low friction). The combination of low friction and negative market direction can drive prices lower faster than normal.

EMISPHERE TECHNOLOGIES INC (OTCBB:EMIS) - Emisphere Technologies, Inc., a biopharmaceutical company, focuses on the delivery of therapeutic molecules and pharmaceutical compounds using its eligen technology. The eligen technology could be applied to the oral route of administration, as well as the other delivery pathways, such as buccal, rectal, inhalation, intra-vaginal, or transdermal. The companys product pipeline includes Oral Salmon Calcitonin, which is in Phase III clinical trials for the treatment of osteoporosis and osteoarthritis; Oral Recombinant Parathyroid Hormone, which is in Phase I clinical trials for the treatment of osteoporosis; and Oral Heparin that is in Phase III clinical trials, as well as Oral Low Molecular Weight Heparin, which is in Phase I clinical trials for the treatment of cardiovascular diseases. Its products under development also comprise Oral Insulin, which is in Phase II clinical trials, as well as Oral Glucagon-Like Peptides, which is in Phase I clinical trials for the treatment of diabetes; Oral Recombinant Human Growth Hormone that is in Phase I clinical trials for the treatment of growth disorders; and Oral Acyclovir, an anti-viral compound that is in Phase I clinical trials. In addition, the companys product pipeline consists of Oral PYY 3-36, which is in Phase I clinical trials for treating obesity; Oral Cromolyn Sodium that is in Phase I clinical trials for the treatment of asthma/allergies; and Oral Gallium, a preclinical stage product candidate, for oncology treatment. Emisphere Technologies has collaboration agreements with Novartis Pharma AG; Roche; and Genta, Inc. The company was founded in 1985. It was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. The company is headquartered in Cedar Knolls, New Jersey.

LIFE PARTNERS HOLDINGS INC (NASDAQ:LPHI) - Life Partners Holdings, Inc., through its subsidiary, Life Partners, Inc., operates as a financial services company that provides purchasing services for life settlements in the United States. It facilitates life settlement transactions by identifying, examining, and purchasing the policies as agent for the purchasers. The companys financial transactions involve the purchase of life insurance policies at a discount to their face value for investment purposes. It serves institutional purchasers, which include investment funds designed to acquire and hold life settlements; and retail purchasers, such as high net worth individuals. The company was founded in 1991 and is based in Waco, Texas.

DOUBLE EAGLE PETROLEUM CO (NASDAQ:DBLE) - Double Eagle Petroleum Co., an energy company, engages in the exploration, development, production, and sale of natural gas and crude oil primarily in the Rocky Mountain Basins of the western United States. The companys principal properties include the Atlantic rim coal bed natural gas project located in south central Wyoming; the Pinedale Anticline property in the Green River basin of Wyoming; the Wind River basin in central Wyoming; and the Moxa Arch and other areas located in southwest Wyoming. It also holds interest in various properties located in North Dakota, Oklahoma, Texas, and Utah. In addition, Double Eagle Petroleum Co. engages in the transportation of gas through its intrastate gas pipeline. As of December 31, 2009, the company had estimated proved reserves of 89.8 billion cubic feet of natural gas and 419 thousand barrels of oil. It also owned interests in a total of 1,172 producing wells and had an interest in 359,830 gross acres natural gas prone basins of the Rocky Mountains. The company was founded in 1972 and is headquartered in Casper, Wyoming.

TOREADOR RESOURCES CORP (NASDAQ:TRGL) - Toreador Resources Corporation, together with its subsidiaries, engages in the acquisition, development, exploration, and production of crude oil. The company primarily holds interests in the two conventional oilfield areas, including the Neocomian Complex and Charmottes fields located in the Paris Basin of France. As of December 31, 2009, the company owned interests in approximately 750,000 gross exploration acres; and had proved plus probable reserves of 9.1 thousand barrels and proved plus probable plus possible reserves of 14.3 thousand barrels. Toreador Resources Corporation was founded in 1951 and is headquartered in Paris, France.

CALLON PETROLEUM CO (NYSE:CPE) - Callon Petroleum Company engages in the acquisition, exploration, development, and production of crude oil and natural gas properties in the onshore in Louisiana and Texas, and the offshore waters of the Gulf of Mexico. As of December 31, 2009, its estimated net proved reserves totaled 58.0 billion cubic feet of natural gas equivalent, including 6.5 million barrels of oil and 19.1 billion cubic feet of natural gas. The company was founded in 1950 and is headquartered in Natchez, Mississippi.

CARDIOME PHARMA CORPORATION (NASDAQ:CRME) - Cardiome Pharma Corp., a life sciences company, focuses on developing drugs to treat or prevent cardiovascular diseases. The companys product pipeline primarily includes Vernakalant (iv), which is in Phase III (ACT 5) clinical trials for the treatment of atrial fibrillation; Vernakalant (oral) that completed Phase IIa clinical trials and Phase IIb clinical trials for the treatment of atrial fibrillation; and GED-aPC, which completed Phase I clinical trials for the treatment of multiple disease states. It has collaboration and license agreements with Merck & Co., Inc. for the development and commercialization of vernakalant; and Astellas Pharma US, Inc. to develop, make, and sell injectable formulations of vernakalant in North America. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is headquartered in Vancouver, Canada.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net